Compare ADMA Biologics Inc (ADMA) vs Philip Morris International Inc. (PM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Philip Morris International Inc. — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Philip Morris International Inc. trades at $187.41 (market cap $287.96B). The key difference: Philip Morris International Inc. is far larger — about 135.2× ADMA Biologics Inc's market cap, and Philip Morris International Inc. pays a 3.18% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | PM | |
|---|---|---|
Market Cap | $2.13B | $287.96B |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $191.86 |
52-Week Low | $7.60 | $144.33 |
Enterprise Value | $2.20B | $334.46B |
Dividend Yield | — | 3.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Philip Morris International (PM) trades at $184.76, up 1.37% with strong technical momentum and bullish moving averages. The company reported solid Q1 2026 earnings beat ($1.96 vs $1.86 expected) and maintains robust profitability with 26.74% net income margin. Recent news includes a $500 million impairment charge on Canadian operations and updated 2026 guidance, though IQOS brand recognition remains a positive catalyst.
PM offers stable revenue growth and strong cash flow generation, but faces headwinds from currency volatility and illicit market pressures. Analyst consensus remains bullish with $194.25 price target (68% buy ratings), though recent profit forecast cuts and high debt levels warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
